Castration-Resistant Prostate Cancer (CRPC); Castration-Resistant Prostate Cancer; Prostate Cancer
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Stage not disclosed · ActiveModality: molecular glue degrader
Target GSPT1
Indications
NSCLC(Phase 2)
SCLC(Phase 2)
High Grade Neuroendocrine Cancer(Phase 2)
Status note GSPT1-directed MGD; clinical trials referenced in primary filing. Stage/indication detail appears only in the 10-K fallback section and is not populated.
MRT-8102
Stage not disclosed · ActiveModality: molecular glue degrader
Target NEK7
Indications
not disclosed(Stage not disclosed)
Status note NEK7-directed MGD; clinical trials referenced in primary filing. Stage/indication detail appears only in the 10-K fallback section and is not populated.
MRT-6160
Stage not disclosed · ActiveModality: molecular glue degrader
Target VAV1
Partnerships Novartis: license agreement (2024) for MRT-6160 and other discovery programs
Indications
not disclosed(Stage not disclosed)
Status note VAV1-directed MGD out-licensed to Novartis; clinical trials referenced in primary filing. Stage/indication detail appears only in the 10-K fallback section and is not populated.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.